QIR-MR

CASIS - CArdiac Simulation & Imaging Software

QIR-MR is a clinical decision support software for the diagnosis, treatment, prevention, or mitigation of cardiovascular conditions. It allows quantitative analyses of cardiovascular Magnetic Resonance (MR) images.

Information source: Vendor
Last updated: June 6, 2024

General Information

General
Product name	QIR-MR
Company	CASIS - CArdiac Simulation & Imaging Software
Subspeciality	Cardiac
Modality	MR
Disease targeted	Myocardial infarction, Myocarditis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Amyloidosis, Fabry disease, Sarcoïdosis, Aortic aneurysm, Iron overload. coronary artery disease, Aortic, mitral and tricuspid valve diseases, stress-induced cardiomyopathy (Tako-Tsubo syndrom)
Key-features	Automatic segmentation, volume quantification and length measurement of the heart chambers, strain quantification, pathological volumes detection and quantification, blood flow/velocities quantification, semi-quantification of the myocardial perfusion
Suggested use	During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion After: diagnosis verification

Technical Specifications

Data characteristics
Population	All adult patients qualified for an MR exam
Input	MR sequences, 2D, 2D+t, cine images, delayed enhancement images (phase-contrast images, first pass dynamic images), aorta images, mapping images (T1,T2,T2*), multi frame
Input format	DICOM
Output	Table of quantified values, analysis report, segmentation overlay, assessment of pathology presence
Output format	CSV, PDF, DICOM SR, HTML, HL7
Technology
Integration	Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment	Locally on dedicated hardware
Trigger for analysis	On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time	10 seconds - 10 minutes ( depends on the type of study)

Regulatory

Certification
CE	Certified, Class IIa , MDD
FDA	510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)

Market

Market presence
On market since	06-2018
Distribution channels
Countries present (clinical, non-research use)	18 countries
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model	Pay-per-use, Subscription, One-time license fee
Based on	Number of users, Number of installations, Number of analyses

Evidence

Evidence
Peer reviewed papers on performance	Automatic deep learning-based myocardial infarction segmentation from delayed enhancement MRI (read) Cardiac MRI Segmentation with Strong Anatomical Guarantee (read)
Non-peer reviewed papers on performance	N/A
Other relevant papers	N/A